Table 2 Details of the Human Participants Included in the Study
No | Current Age of Cancer Survivor | Age at Diagnosis of Cancer | Type of Cancer; Treatment Regimen given to Treat Cancer (with alkylating agent doses) | Semen Analysis | FSH | Testo-sterone |
|---|---|---|---|---|---|---|
1 | 35 years | 12 years | Hodgkin’s Lymphoma; CT + RT CT : Cyclophosphamide-9.6gm/m2 RT to bilateral neck 40Gy/20# | Azoospermia | - | - |
2 | 35Â years | 12.6Â years | Lymphoblastic lymphoma;CT+ RT CT : Cyclophosphamide 22.4gm/m2 RT : Cranial 18Gy/9# Mediastinum 40Â Gy/20# | Azoospermia | - | - |
3 | 30 year | 5 years at first diagnosis 27 years at recurrence | Non Hodgkin’s lymphoma with recurrence/ transformation to Diffuse Large B cell Lymphoma Surgery + CT+ RT Surgery-Right Orchiectomy CT: Cyclophosphamide 16gm/m2 RT: Cranial 18Gy/9# CT alone Cyclophosphamide-5.5 gm/m2 | Azoospermia | WNL | WNL |
4 | 35 years | 8 years | Wilms tumor : Surgery + CT+ RT Surgery-Left nephrectomy CT: Cyclophosphamide-10.8 gm/m2, RT to left renal fossa 20 Gy/7# | Azoospermia | Elevated | WNL |
5 | 28 years | 7 years | Hodgkin Lymphoma; CT + RT CT : Cyclophosphamide- 9.3 gm/m2; Procarbazine-10 gm/m2 RT to bilateral neck 36 Gy/18# | Azoospermia | Elevated | WNL |
6 | 23 years | 13 years | Non Hodgkin lymphoma;CT + RT CT :Cyclophosphamide 20 g/m2 RT: Cranial 19.8Gy/11# | Azoospermia | Elevated | Elevated |
7 | 25 years | 10 year | Non Hodgkin lymphoma; CT + RT CT : Cyclophosphamide 19gm/m2 RT: Cranial 19.8Gy/11# | Azoospermia | Elevated | Elevated |